

# Siamak Daneshmand

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/586236/publications.pdf>

Version: 2024-02-01

366  
papers

13,943  
citations

26567

56  
h-index

27345

106  
g-index

375  
all docs

375  
docs citations

375  
times ranked

11644  
citing authors

#	ARTICLE	IF	CITATIONS
1	Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patientâ€™s undergoing urologic oncology surgery: a systematic review. World Journal of Urology, 2022, 40, 1325-1342.	1.2	21
2	Macro and microeconomics of blue light cystoscopy with CYSVIEWÂ® in non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 10.e7-10.e12.	0.8	4
3	Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. Journal of Urology, 2022, 207, 70-76.	0.2	15
4	An emerging role for immuno-nutrition in patients undergoing radical cystectomy. Nature Reviews Urology, 2022, 19, 1-2.	1.9	6
5	Utility of Blue Light Cystoscopy for Post-bacillus Calmette-GuÃ©rin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons. Journal of Urology, 2022, 207, 534-540.	0.2	4
6	Safety and feasibility of urological procedures in Jehovahâ€™s Witness patients. International Journal of Urology, 2022, 29, 83-88.	0.5	3
7	Role of blueâ€light cystoscopy in detecting invasive bladder tumours: data from a multiâ€institutional registry. BJU International, 2022, 130, 62-67.	1.3	6
8	Clinical stage II seminoma: management options. World Journal of Urology, 2022, 40, 343-348.	1.2	7
9	Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 35-42.	0.9	5
10	Risk factors and natural history of parastomal hernia after radical cystectomy and ileal conduit. BJU International, 2022, 130, 381-388.	1.3	7
11	Reply by Authors. Journal of Urology, 2022, 207, 313-313.	0.2	0
12	Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases. Journal of Urology, 2022, 207, 302-313.	0.2	31
13	Longâ€term renal function in patients with chronic kidney disease following radical cystectomy and orthotopic neobladder. BJU International, 2022, 130, 200-207.	1.3	6
14	Bladder Recurrence Following Diagnostic Ureteroscopy in Patients Undergoing Nephroureterectomy for Upper Tract Urothelial Cancer: Is Ureteral Access Sheath Protective?. Urology, 2022, 160, 142-146.	0.5	10
15	Re: Detection rate of CIS during TURBT following shift from PDD to NBI in a single University Hospital. Urology, 2022, , .	0.5	0
16	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. Cancers, 2022, 14, 1781.	1.7	1
17	The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 344.e1-344.e9.	0.8	5
18	Association between use of ERAS protocols and complications after radical cystectomy. World Journal of Urology, 2022, 40, 1311-1316.	1.2	4

#	ARTICLE	IF	CITATIONS
19	Targeting <i>FGFR3</i> alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. <i>Future Oncology</i> , 2022, 18, 2599-2614.	1.1	10
20	Chronic kidney disease and radical cystectomy for bladder cancer: perioperative and oncologic outcomes in 1,214 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 381.e9-381.e16.	0.8	3
21	Association Study between Polymorphisms in DNA Methylation-Related Genes and Testicular Germ Cell Tumor Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1769-1779.	1.1	4
22	Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 382.e1-382.e6.	0.8	3
23	Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. <i>BJU International</i> , 2021, 128, 79-87.	1.3	10
24	Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. <i>European Urology</i> , 2021, 79, 16-19.	0.9	36
25	Feasibility and Outcomes of Orthotopic Ileal Neobladder Reconstruction Following Pelvic Irradiation. <i>Urology</i> , 2021, 148, 198-202.	0.5	2
26	Stoma complications and quality of life in patients with Indiana pouch versus appendico/neo-appendico-umbilicostomy urinary diversions. <i>World Journal of Urology</i> , 2021, 39, 1521-1529.	1.2	3
27	Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. <i>BJU International</i> , 2021, 127, 108-113.	1.3	11
28	Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. <i>European Urology Oncology</i> , 2021, 4, 12-19.	2.6	26
29	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021, 127, 528-537.	1.3	10
30	Predictors of need for catheterisation and urinary retention after radical cystectomy and orthotopic neobladder in male patients. <i>BJU International</i> , 2021, 128, 304-310.	1.3	3
31	Preoperative chemotherapy in clinically node positive muscle invasive bladder cancer: Radiologic variables can predict response. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 133.e1-133.e8.	0.8	6
32	Multiparametric cystoscopy: is the future here yet?. <i>Translational Andrology and Urology</i> , 2021, 10, 1-6.	0.6	2
33	Radical Cystectomy. , 2021, , 139-175.		0
34	Discrepancies in the Recommended Management of Adrenal Incidentalomas by Various Guidelines. <i>Journal of Urology</i> , 2021, 205, 52-59.	0.2	16
35	SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 375-375.	0.8	28
36	A Novel DNA Methylation Signature as an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 614927.	1.3	5

#	ARTICLE	IF	CITATIONS
37	A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). <i>Clinical Cancer Research</i> , 2021, 27, 2435-2441.	3.2	46
38	Disparities in male versus female oncologic outcomes following bladder preservation: A population-based cohort study. <i>Cancer Medicine</i> , 2021, 10, 3004-3012.	1.3	6
39	Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples. <i>Clinical Epigenetics</i> , 2021, 13, 84.	1.8	15
40	Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. <i>European Urology Oncology</i> , 2021, 4, 170-179.	2.6	28
41	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 525-537.	5.1	225
42	Enhanced recovery after cystectomy in patients with preoperative narcotic use. <i>Canadian Urological Association Journal</i> , 2021, 15, E563-E568.	0.3	1
43	Evaluation of Bowel Function Following Radical Cystectomy and Urinary Diversion Using Two Validated Questionnaires: What Are the Effects on Quality of Life?. <i>Urology</i> , 2021, 156, 279-284.	0.5	3
44	Enhanced Endoscopy with IMAGE1 S CHROMA Improves Detection of Nonmuscle Invasive Bladder Cancer During Transurethral Resection. <i>Journal of Endourology</i> , 2021, 35, 647-651.	1.1	4
45	Perioperative outcomes of goal-directed versus conventional fluid therapy in radical cystectomy with enhanced recovery protocol. <i>International Urology and Nephrology</i> , 2021, 53, 1827-1833.	0.6	10
46	Diagnosis and Staging of Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 531-541.	0.9	31
47	Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer. <i>Anticancer Research</i> , 2021, 41, 3851-3857.	0.5	1
48	Patient Reported Sexual Function Outcomes in Male Patients Following Open Radical Cystoprostatectomy and Urinary Diversion. <i>Urology</i> , 2021, , .	0.5	3
49	A Massive Penile Tumor. <i>Urology</i> , 2021, 154, e5-e6.	0.5	0
50	Vena Cava Tumor Thrombus Associated With Renal Angiomyolipoma in a Jehovah's Witness Patient. <i>Urology</i> , 2021, 156, e86-e87.	0.5	2
51	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	1.2	4
52	MicroRNA-371a-3p as a blood-based biomarker in testis cancer. <i>Asian Journal of Urology</i> , 2021, 8, 400-406.	0.5	2
53	Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis. <i>Cancers</i> , 2021, 13, 4378.	1.7	35
54	The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 206, 1380-1389.	0.2	8

#	ARTICLE	IF	CITATIONS
55	Development and Validation of an Objective Scoring Tool to Evaluate Surgical Dissection: Dissection Assessment for Robotic Technique (DART). <i>Urology Practice</i> , 2021, 8, 596-604.	0.2	6
56	Validation of the COBRA nomogram for the prediction of cancer specific survival in patients treated with radical cystectomy for bladder cancer: An international wide cohort study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2646-2650.	0.5	4
57	Intricacies of retroperitoneal lymph node dissection for testis cancer. <i>Current Opinion in Urology</i> , 2021, Publish Ahead of Print, 24-30.	0.9	4
58	National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013. <i>European Urology Oncology</i> , 2020, 3, 343-350.	2.6	6
59	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	0.8	29
60	Voiding Dysfunction After Neobladder Urinary Diversion. <i>Current Bladder Dysfunction Reports</i> , 2020, 15, 38-43.	0.2	1
61	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 916-924.	0.9	18
62	Reply to Gianluca Giannarini, Vincenzo Ficarra, and Claudio Valotto's Letter to the Editor re: Stephen B. Williams, Marcus G.K. Cumberbatch, Ashish M. Kamat, et al. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2020.06.039">https://doi.org/10.1016/j.eururo.2020.06.039</a> . <i>European Urology</i> , 2020, 78, e190-e191.	0.9	2
63	Quality reporting in postchemotherapy retroperitoneal lymph node dissection. <i>Cancer</i> , 2020, 126, 4825-4825.	2.0	0
64	EDITORIAL COMMENT. <i>Urology</i> , 2020, 140, 120-121.	0.5	0
65	AUTHOR REPLY. <i>Urology</i> , 2020, 142, 154.	0.5	0
66	Impact of Non-guideline-directed Care on Quality of Life in Testicular Cancer Survivors. <i>European Urology Focus</i> , 2020, 7, 1137-1142.	1.6	5
67	Perioperative complications and oncological outcomes following radical cystectomy among different racial groups: A long-term, single-center study. <i>Canadian Urological Association Journal</i> , 2020, 14, E493-E498.	0.3	2
68	Occult Nodal Metastases in Patients Down-Staged to Nonmuscle Invasive Disease Following Neoadjuvant Chemotherapy. <i>Urology</i> , 2020, 142, 155-160.	0.5	10
69	Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. <i>European Urology</i> , 2020, 77, 669-670.	0.9	30
70	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. <i>Cancer</i> , 2020, 126, 2597-2606.	2.0	39
71	Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. <i>European Urology</i> , 2020, 78, 719-730.	0.9	73
72	Adult genitourinary sarcoma: A population-based analysis of clinical characteristics and survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 334-343.	0.8	17

#	ARTICLE	IF	CITATIONS
73	Editorial. Current Opinion in Urology, 2020, 30, 234.	0.9	1
74	Internal audit of an enhanced recovery after surgery protocol for radical cystectomy. World Journal of Urology, 2020, 38, 3131-3137.	1.2	9
75	Detecting Invisible Bladder Cancers With Blue Light Cystoscopy. Urology, 2020, 139, e8-e9.	0.5	2
76	Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature. Clinical Genitourinary Cancer, 2020, 18, e473-e477.	0.9	1
77	Role of primary retroperitoneal lymph node dissection in stage I and low-volume metastatic germ cell tumors. Current Opinion in Urology, 2020, 30, 251-257.	0.9	8
78	Bladder Cancer: Advances and Innovations. European Urology Focus, 2020, 6, 613-614.	1.6	7
79	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 639.e1-639.e9.	0.8	15
80	Surgical strategies for postchemotherapy testis cancer. Translational Andrology and Urology, 2020, 9, S74-S82.	0.6	3
81	Urinary tract infections following radical cystectomy with enhanced recovery protocol: A prospective study. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 75.e9-75.e14.	0.8	17
82	Perioperative Outcome of Suprarenal Resection of Vena Cava Without Reconstruction in Urologic Malignancies: A Case Series and Review of the Literature. Urology, 2020, 142, 146-154.	0.5	9
83	Zero, Some Chemotherapy Game in Early-Stage Germ Cell Tumors. Journal of Clinical Oncology, 2020, 38, 2214-2215.	0.8	2
84	Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. European Urology Focus, 2020, 6, 639-641.	1.6	16
85	Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 796.e1-796.e6.	0.8	13
86	Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings.. Journal of Clinical Oncology, 2020, 38, 5038-5038.	0.8	4
87	PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible <i>FGFR3</i> alterations.. Journal of Clinical Oncology, 2020, 38, TPS5095-TPS5095.	0.8	9
88	PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring <i>FGFR3</i> alterations.. Journal of Clinical Oncology, 2020, 38, TPS600-TPS600.	0.8	8
89	A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.. Journal of Clinical Oncology, 2020, 38, TPS603-TPS603.	0.8	10
90	ERAS for Major Urological Procedures: Evidence Synthesis and Recommendations. , 2020, , 421-431.		0

#	ARTICLE	IF	CITATIONS
91	Comparison between oncological outcomes of primary versus salvage radical cystectomy for urothelial carcinoma of the bladder.. Journal of Clinical Oncology, 2020, 38, 585-585.	0.8	1
92	Oncological outcomes following radical cystectomy for urothelial carcinoma of the bladder with positive lymph nodes.. Journal of Clinical Oncology, 2020, 38, 584-584.	0.8	4
93	Active surveillance for low-risk prostate cancer " in pursuit of a standardized protocol. Central European Journal of Urology, 2020, 73, 123-126.	0.2	1
94	Current controversies on the role of lymphadenectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 193-200.	0.8	6
95	Validating the role of ABO blood type in risk of perioperative venous thromboembolism after radical cystectomy. World Journal of Urology, 2019, 37, 173-179.	1.2	4
96	Growing Teratoma Syndrome of Testicular Origin. Urology, 2019, 123, 20-23.	0.5	2
97	Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. BJU International, 2019, 123, 35-41.	1.3	16
98	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer, 2019, 125, 3853-3863.	2.0	4
99	Surgical approach as a determinant factor of clinical outcome following radical cystectomy: Does Enhanced Recovery After Surgery (ERAS) level the playing field?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 765-773.	0.8	21
100	Factors influencing ICU admission and associated outcome in patients undergoing radical cystectomy with enhanced recovery pathway. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 572.e13-572.e19.	0.8	5
101	Postchemotherapy Resection of Residual Mass in Nonseminomatous Germ Cell Tumor. Urologic Clinics of North America, 2019, 46, 389-398.	0.8	14
102	Advanced Testis Cancer. European Urology Focus, 2019, 5, 710-712.	1.6	1
103	Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. Journal of Clinical Oncology, 2019, 37, 3090-3098.	0.8	81
104	Assessing the Impact of Time to Cystectomy for Variant Histology of Urothelial Bladder Cancer. Urology, 2019, 133, 157-163.	0.5	8
105	Testicular Mesothelioma: An Analysis of Epidemiology, Patient Outcomes, and Prognostic Factors. Urology, 2019, 126, 140-144.	0.5	16
106	SIU "ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World Journal of Urology, 2019, 37, 61-83.	1.2	40
107	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. European Journal of Surgical Oncology, 2019, 45, 1983-1992.	0.5	18
108	Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. European Urology, 2019, 76, 238-243.	0.9	29

#	ARTICLE	IF	CITATIONS
109	Preoperative chemotherapy for prostatic stromal invasive urothelial bladder cancer: comparison of oncological outcomes of male patients with cT4a disease undergoing radical cystectomy with or without preoperative chemotherapy. <i>Scandinavian Journal of Urology</i> , 2019, 53, 123-128.	0.6	0
110	Socioeconomic and insurance status are independent prognostic indicators of higher disease stage and worse prognosis in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 784-790.	0.8	16
111	Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA " update 2018. <i>Nature Reviews Urology</i> , 2019, 16, 377-386.	1.9	51
112	Management of extraretroperitoneal masses in germ cell tumor. <i>Current Opinion in Urology</i> , 2019, 29, 33-41.	0.9	4
113	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3908-3920.	3.2	71
114	Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. <i>European Urology Oncology</i> , 2019, 2, 119-125.	2.6	16
115	High-grade T1 Urothelial Carcinoma: Where Do We Stand?. <i>Current Urology Reports</i> , 2019, 20, 79.	1.0	4
116	Preface. <i>Urologic Clinics of North America</i> , 2019, 46, xiii.	0.8	0
117	Frailty and preoperative risk assessment before radical cystectomy. <i>Current Opinion in Urology</i> , 2019, 29, 216-219.	0.9	12
118	Assessing trends in urinary diversion after radical cystectomy for bladder cancer in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 180.e1-180.e9.	0.8	14
119	Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 48-56.	0.8	21
120	Frailty as a predictor of complications after radical cystectomy: A prospective study of various preoperative assessments. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 40-47.	0.8	47
121	Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 1-11.	0.8	11
122	Factors influencing intraoperative conversion from planned orthotopic to non-orthotopic urinary diversion during radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 1851-1855.	1.2	7
123	Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy. <i>International Urology and Nephrology</i> , 2019, 51, 435-441.	0.6	8
124	Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. <i>Journal of Urology</i> , 2019, 202, 272-281.	0.2	157
125	Development and Acceptability Testing of a Patient Decision Aid for Urinary Diversion with Radical Cystectomy. <i>Journal of Urology</i> , 2019, 202, 1001-1007.	0.2	23
126	SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4506-4506.	0.8	26



#	ARTICLE	IF	CITATIONS
127	Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.. Journal of Clinical Oncology, 2019, 37, 4510-4510.	0.8	7
128	Validation of plasma miR-371a-3p expression in patients with metastatic and early stage germ cell tumor.. Journal of Clinical Oncology, 2019, 37, 526-526.	0.8	1
129	Cell-free DNA (cfDNA) whole genome bisulfite sequencing in patients with muscle-invasive bladder cancer patient treated with cystectomy with curative intent.. Journal of Clinical Oncology, 2019, 37, 359-359.	0.8	0
130	Epigenomic profiling of plasma cell-free DNA (cfDNA) to predict bladder cancer recurrence after radical cystectomy.. Journal of Clinical Oncology, 2019, 37, e14525-e14525.	0.8	0
131	Retroperitoneal Lymph Node Dissection as an Alternative Treatment Strategy for Low Volume, Clinical Stage II Testicular Seminoma: A Survey of Patients and Providers. Urology Practice, 2019, 6, 249-255.	0.2	0
132	Enhanced Recovery After Surgery Pathways. Urologic Clinics of North America, 2018, 45, 229-239.	0.8	5
133	Urinary tract infections following radical cystectomy and urinary diversion: a review of 1133 patients. World Journal of Urology, 2018, 36, 775-781.	1.2	36
134	Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. Journal of Urology, 2018, 199, 1158-1165.	0.2	82
135	Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aNOMO Bladder Cancer Treated with Radical Cystectomy. Journal of Urology, 2018, 199, 1452-1458.	0.2	61
136	The association between intraoperative fluid intake and postoperative complications in patients undergoing radical cystectomy with an enhanced recovery protocol. World Journal of Urology, 2018, 36, 401-407.	1.2	18
137	Satisfaction With Testicular Prosthesis After Radical Orchiectomy. Urology, 2018, 114, 128-132.	0.5	20
138	Association between race and oncologic outcome following radical prostatectomy for clinically organ-confined prostate cancer: a long-term follow-up study. World Journal of Urology, 2018, 36, 1233-1239.	1.2	6
139	Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy. European Urology Focus, 2018, 4, 245-251.	1.6	24
140	Readmission Following Radical Cystectomy: A Ray of Light in the "Black Box". European Urology Focus, 2018, 4, 718-719.	1.6	0
141	Gastrointestinal Complications Following Radical Cystectomy Using Enhanced Recovery Protocol. European Urology Focus, 2018, 4, 889-894.	1.6	39
142	Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients. Clinical Genitourinary Cancer, 2018, 16, 90-98.e1.	0.9	11
143	Vena Cavoscopy in the Assessment of Intraluminal Vena Caval Tumor Involvement. Urology, 2018, 113, 105-109.	0.5	1
144	Continent Cutaneous Diversion. Urologic Clinics of North America, 2018, 45, 55-65.	0.8	14

#	ARTICLE	IF	CITATIONS
145	The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2018, 73, 543-557.	0.9	105
146	Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 79.e11-79.e17.	0.8	14
147	The impact of patient-related nonmodifiable factors on perioperative outcomes following radical cystectomy with enhanced recovery protocol. <i>Therapeutic Advances in Urology</i> , 2018, 10, 393-401.	0.9	11
148	Modern Management of Testicular Cancer. <i>Cancer Treatment and Research</i> , 2018, 175, 273-308.	0.2	8
149	Molecular Prognostication in Bladder Cancer. <i>Cancer Treatment and Research</i> , 2018, 175, 165-191.	0.2	5
150	Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma. <i>Advances in Urology</i> , 2018, 2018, 1-5.	0.6	18
151	Enhanced Endoscopy in Bladder Cancer. <i>Current Urology Reports</i> , 2018, 19, 84.	1.0	13
152	Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 361.e1-361.e6.	0.8	79
153	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , 2018, 23, 3392-3406.	2.9	324
154	Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. <i>European Urology Oncology</i> , 2018, 1, 223-230.	2.6	25
155	Optimizing Diagnosis of Urothelial Bladder Cancer with Blue Light Cystoscopy via Recognition of False-Positive Lesions. <i>Videourology (New Rochelle, N Y)</i> , 2018, 32, .	0.1	2
156	Circulating miR-371a-3p for the detection of low volume viable germ cell tumor: Expanded pilot data, clinical implications and future study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4549-4549.	0.8	8
157	Effectiveness of extended pelvic lymphadenectomy in the survival of prostate cancer: a systematic review and meta-analysis. <i>Central European Journal of Urology</i> , 2018, 71, 262-269.	0.2	13
158	Lymph node dissection in bladder cancer: Where do we stand?. <i>World Journal of Urology</i> , 2017, 35, 527-533.	1.2	9
159	Oncological Outcomes After Radical Prostatectomy for High-Risk Prostate Cancer Based on New Gleason Grouping System: A Validation Study From University of Southern California With 3,755 Cases. <i>Prostate</i> , 2017, 77, 743-748.	1.2	10
160	Transurethral Resection of Bladder Tumors: Improving Quality Through New Techniques and Technologies. <i>Current Urology Reports</i> , 2017, 18, 34.	1.0	21
161	Restrictive transfusion in radical cystectomy is safe. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 528.e15-528.e21.	0.8	11
162	Dose dense MVAC prior to radical cystectomy: a real-world experience. <i>World Journal of Urology</i> , 2017, 35, 1729-1736.	1.2	8

#	ARTICLE	IF	CITATIONS
163	Orthotopic Urinary Diversion in Men. , 2017, , 11-24.		1
164	Tolerance of Orthotopic Ileal Neobladders to Radiotherapy: A Multi-institutional Retrospective Study. Clinical Genitourinary Cancer, 2017, 15, 711-716.	0.9	16
165	Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study. Clinical Genitourinary Cancer, 2017, 15, 689-695.e2.	0.9	14
166	Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical Morbidity. European Urology, 2017, 72, 814-820.	0.9	30
167	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 2017, 171, 540-556.e25.	13.5	1,742
168	90-Day complication rate in patients undergoing radical cystectomy with enhanced recovery protocol: a prospective cohort study. World Journal of Urology, 2017, 35, 907-911.	1.2	90
169	Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer. Journal of Urology, 2017, 197, 684-689.	0.2	52
170	Feasibility of expert and crowd-sourced review of intraoperative video for quality improvement of intracorporeal urinary diversion during robotic radical cystectomy. Canadian Urological Association Journal, 2017, 11, 331-6.	0.3	9
171	Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. Journal of Clinical Oncology, 2017, 35, 3525-3528.	0.8	56
172	Stomal Complications. , 2017, , 121-141.		1
173	Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients. Prostate, 2016, 76, 1239-1256.	1.2	20
174	Utilization of retroperitoneal lymph node dissection for testicular cancer in the United States: Results from the National Cancer Database (1998â€“2011). Urologic Oncology: Seminars and Original Investigations, 2016, 34, 487.e7-487.e11.	0.8	15
175	Cost Analysis of the Enhanced Recovery After Surgery Protocol in Patients Undergoing Radical Cystectomy for Bladder Cancer. European Urology Focus, 2016, 2, 92-96.	1.6	40
176	Incisional and Parastomal Hernia following Radical Cystectomy and Urinary Diversion: The University of Southern California Experience. Journal of Urology, 2016, 196, 777-781.	0.2	34
177	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. Journal of Clinical Oncology, 2016, 34, 2478-2483.	0.8	31
178	Gastrointestinal Complications in Patients Who Undergo Radical Cystectomy with Enhanced Recovery Protocol. Current Urology Reports, 2016, 17, 50.	1.0	20
179	Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures. Journal of Urology, 2016, 196, 1036-1041.	0.2	33
180	Assessment of Urologists' Knowledge of Intraoperative Floppy Iris Syndrome. Urology, 2016, 97, 40-45.	0.5	5

#	ARTICLE	IF	CITATIONS
181	Preoperative Imaging for Clinical Staging Prior to Radical Cystectomy. <i>Current Urology Reports</i> , 2016, 17, 62.	1.0	7
182	Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2016, 196, 1627-1633.	0.2	36
183	Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. <i>Journal of Urology</i> , 2016, 196, 1021-1029.	0.2	971
184	Editorial Comment. <i>Journal of Urology</i> , 2016, 195, 1716-1716.	0.2	0
185	Prospective Evaluation of Continence Following Radical Cystectomy and Orthotopic Urinary Diversion Using a Validated Questionnaire. <i>Journal of Urology</i> , 2016, 196, 1685-1691.	0.2	36
186	Radical cystectomy with superextended lymphadenectomy: impact of separate vs en bloc lymph node submission on analysis and outcomes. <i>BJU International</i> , 2016, 117, 253-259.	1.3	17
187	Utility and significance of ureteric frozen section analysis during radical cystectomy. <i>BJU International</i> , 2016, 117, 463-468.	1.3	28
188	Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?. <i>Journal of Urology</i> , 2016, 195, 886-893.	0.2	71
189	Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. <i>European Urology</i> , 2016, 69, 300-310.	0.9	460
190	Orthotopic urinary diversion in the elderly. <i>World Journal of Urology</i> , 2016, 34, 13-18.	1.2	9
191	Robotic Intracorporeal Orthotopic Neobladder: Urodynamic Outcomes, Urinary Function, and Health-related Quality of Life. <i>European Urology</i> , 2016, 69, 247-253.	0.9	77
192	A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. <i>Journal of Urology</i> , 2016, 195, 53-59.	0.2	95
193	Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 393-393.	0.8	1
194	Baseline GFR and cisplatin-induced renal toxicity in urothelial cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 380-380.	0.8	0
195	Development and validation of contouring guidelines for post-cystectomy adjuvant radiation of bladder cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 409-409.	0.8	6
196	Blue Light Cystoscopy with Cysview: The USC Experience. <i>Videourology (New Rochelle, N Y)</i> , 2016, 30, .	0.1	0
197	Adjuvant chemotherapy for bladder cancer: A detailed characterization of factors precluding utilization.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16001-e16001.	0.8	0
198	The opportunity cost (OC) of performing radical prostatectomy (RP) by low volume (LV) providers (Prov).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6509-6509.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Outcomes in neuroendocrine bladder cancer treated with radical cystectomy.. Journal of Clinical Oncology, 2016, 34, e16004-e16004.	0.8	0
200	An extraperitoneal midline approach to retroperitoneal lymph node dissection to minimize bowel morbidity.. Journal of Clinical Oncology, 2016, 34, e16042-e16042.	0.8	0
201	Frailty as a predictor of complications in older patients undergoing radical cystectomy.. Journal of Clinical Oncology, 2016, 34, e16007-e16007.	0.8	0
202	Female cystectomy with orthotopic urinary diversion: Is fear of urethral recurrence justified?. Journal of Clinical Oncology, 2016, 34, e16006-e16006.	0.8	0
203	Urinary diversion 2015. Current Opinion in Urology, 2015, 25, 543-544.	0.9	3
204	Orthotopic urinary diversion. Current Opinion in Urology, 2015, 25, 545-549.	0.9	18
205	Is Frozen Section Analysis of Ureteral Margins at Time of Radical Cystectomy Useful?. Current Urology Reports, 2015, 16, 38.	1.0	10
206	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2015, 67, 241-249.	0.9	235
207	Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. Journal of Urology, 2015, 193, 436-442.	0.2	27
208	Venous Thromboembolism Following Radical Cystectomy: Significant Predictors, Comparison of Different Anticoagulants and Timing of Events. Journal of Urology, 2015, 193, 565-569.	0.2	56
209	Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy. World Journal of Urology, 2015, 33, 1419-1428.	1.2	19
210	Continent Urinary Diversion in the Elderly. Current Geriatrics Reports, 2015, 4, 1-6.	1.1	3
211	Role of Extraretroperitoneal Surgery in Patients with Metastatic Germ Cell Tumors. Urologic Clinics of North America, 2015, 42, 369-380.	0.8	14
212	Randomized Trial of Studer Pouch versus T-Pouch Orthotopic Ileal Neobladder in Patients with Bladder Cancer. Journal of Urology, 2015, 194, 433-440.	0.2	41
213	Role of surgical resection for refractory germ cell tumors. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 370-378.	0.8	17
214	Female reproductive organ-sparing radical cystectomy. Current Opinion in Urology, 2015, 25, 105-110.	0.9	21
215	Retroperitoneal Lymph Node Dissection as First-Line Treatment of Node-Positive Seminoma. Clinical Genitourinary Cancer, 2015, 13, e265-e269.	0.9	31
216	Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. Journal of Urology, 2015, 194, 304-309.	0.2	28

#	ARTICLE	IF	CITATIONS
217	Postoperative Pain Management after Radical Cystectomy: Comparing Traditional versus Enhanced Recovery Protocol Pathway. <i>Journal of Urology</i> , 2015, 194, 1209-1213.	0.2	90
218	Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance. <i>Journal of Clinical Oncology</i> , 2015, 33, 51-57.	0.8	268
219	Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4568-4568.	0.8	1
220	The Role of Lymphadenectomy in the Management of Urothelial Carcinoma of the Upper Urinary Tract. , 2015, , 153-178.		0
221	Predicting survival after radical cystectomy: Validation of the SPARC score.. <i>Journal of Clinical Oncology</i> , 2015, 33, 326-326.	0.8	2
222	Radiosensitivity of orthotopic ileal neobladders.. <i>Journal of Clinical Oncology</i> , 2015, 33, 350-350.	0.8	0
223	Oncological outcomes in high-risk prostate cancer after radical prostatectomy based on Gleason score: USC experience with 3,755 cases.. <i>Journal of Clinical Oncology</i> , 2015, 33, 60-60.	0.8	0
224	Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes. <i>Patient Related Outcome Measures</i> , 2014, 5, 63.	0.7	41
225	Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. <i>BMC Cancer</i> , 2014, 14, 966.	1.1	24
226	Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy. <i>BJU International</i> , 2014, 113, 554-560.	1.3	43
227	The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer. <i>BJU International</i> , 2014, 113, 887-893.	1.3	80
228	Outcomes After Urothelial Recurrence in Bladder Cancer Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2014, 84, 1420-1426.	0.5	38
229	Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. <i>Nature Reviews Urology</i> , 2014, 11, 589-596.	1.9	69
230	Significance of perivesical lymph nodes in radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1158-1165.	0.8	10
231	Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. <i>BJU International</i> , 2014, 113, 11-23.	1.3	274
232	Enhanced recovery pathway following radical cystectomy. <i>Current Opinion in Urology</i> , 2014, 24, 135-139.	0.9	18
233	Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	46
234	Reprogramming of the human intestinal epigenome by surgical tissue transposition. <i>Genome Research</i> , 2014, 24, 545-553.	2.4	16

#	ARTICLE	IF	CITATIONS
235	Mesenteric Lymphadenopathy in Testicular Germ Cell Tumor. <i>Urology</i> , 2014, 83, e7-e8.	0.5	9
236	Enhanced Recovery Protocol after Radical Cystectomy for Bladder Cancer. <i>Journal of Urology</i> , 2014, 192, 50-56.	0.2	212
237	Urinary functional outcomes in female neobladder patients. <i>World Journal of Urology</i> , 2014, 32, 221-228.	1.2	41
238	Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: Results from a prospective lymph node mapping study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 24.e13-24.e19.	0.8	33
239	Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 230-242.	0.8	33
240	Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 120-137.	0.9	277
241	Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 110-116.	0.8	49
242	Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 85-91.	0.8	5
243	Growing teratoma syndrome: Clinical and radiographic characteristics. <i>International Journal of Urology</i> , 2014, 21, 905-908.	0.5	30
244	Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 117-127.	0.8	87
245	Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. <i>Journal of Urology</i> , 2014, 191, 40-47.	0.2	153
246	Level III-IV Inferior Vena Caval Thrombectomy Without Cardiopulmonary Bypass: Long-Term Experience with Intrapericardial Control. <i>Journal of Urology</i> , 2014, 192, 682-689.	0.2	39
247	Precystectomy serum levels of carbohydrate antigen 19-9, carbohydrate antigen 125, and carcinoembryonic antigen: Prognostic value in invasive urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 648-656.	0.8	19
248	Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 52.e1-52.e9.	0.8	55
249	Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. <i>European Urology</i> , 2014, 66, 577-583.	0.9	76
250	A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence. <i>Clinical Cancer Research</i> , 2014, 20, 1978-1989.	3.2	77
251	Validation of Surveillance, Epidemiology, and End Results TNM staging for testicular germ cell tumor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1341-1346.	0.8	17
252	Outcome in patients with exclusive carcinoma <i>in situ</i> (cIS) after radical cystectomy. <i>BJU International</i> , 2014, 113, 65-69.	1.3	13

#	ARTICLE	IF	CITATIONS
253	Association of higher institutional volume with improved overall survival in clinical stage III testicular cancer: Results from the National Cancer Data Base (1998-2011).. Journal of Clinical Oncology, 2014, 32, 4519-4519.	0.8	5
254	Prerandomization factors and utilization of neoadjuvant chemotherapy in a clinical trial of extended versus standard pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer.. Journal of Clinical Oncology, 2014, 32, 295-295.	0.8	1
255	Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2014, 32, 324-324.	0.8	4
256	Evaluation of length, maximum Gleason score, and extension of disease at positive surgical margins during radical prostatectomy.. Journal of Clinical Oncology, 2014, 32, 98-98.	0.8	0
257	Decreasing length of hospital stay following radical cystectomy using multimodal enhanced recovery protocol.. Journal of Clinical Oncology, 2014, 32, 313-313.	0.8	0
258	Venothromboembolism and radical cystectomy: Prevalence of risk factors and comparison of anticoagulation use.. Journal of Clinical Oncology, 2014, 32, 339-339.	0.8	0
259	Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: Results of the international collaboration on primary urethral carcinoma.. Journal of Clinical Oncology, 2014, 32, 4587-4587.	0.8	1
260	Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU International, 2013, 111, 249-255.	1.3	67
261	Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. BJU International, 2013, 111, 74-84.	1.3	26
262	Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU International, 2013, 112, E51-8.	1.3	82
263	Incidental Prostate Cancer in Patients with Bladder Urothelial Carcinoma: Comprehensive Analysis of 1,476 Radical Cystoprostatectomy Specimens. Journal of Urology, 2013, 190, 1704-1709.	0.2	46
264	Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1441-1447.	0.8	24
265	Androgen deprivation therapy: evidence-based management of side effects. BJU International, 2013, 111, 543-548.	1.3	128
266	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. European Urology, 2013, 63, 371-378.	0.9	47
267	A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer. BJU International, 2013, 111, 240-248.	1.3	45
268	Long-term outcomes of salvage radical cystectomy for recurrent urothelial carcinoma of the bladder following partial cystectomy. BJU International, 2013, 111, E37-42.	1.3	17
269	Urinary Functional Outcome Following Radical Cystoprostatectomy and Ileal Neobladder Reconstruction in Male Patients. Journal of Urology, 2013, 189, 1782-1788.	0.2	89
270	Conversion From Incontinent Conduit to Continent Cutaneous Reservoir After Renal Transplant. Urology, 2013, 81, 1086-1089.	0.5	0



#	ARTICLE	IF	CITATIONS
271	Determining the Role of Cystectomy for High-grade T1 Urothelial Carcinoma. <i>Urologic Clinics of North America</i> , 2013, 40, 233-247.	0.8	15
272	Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. <i>European Urology</i> , 2013, 64, 837-845.	0.9	61
273	Editorial Comment. <i>Journal of Urology</i> , 2013, 190, 927-927.	0.2	0
274	Minimally Invasive Postchemotherapy Retroperitoneal Lymph Node Dissection: Caution and Prudence. <i>European Urology</i> , 2013, 63, 1018-1019.	0.9	5
275	Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California. <i>Urologic Oncology: Seminars and Original Investigations</i> . 2013. 31. 1737-1743.	0.8	57
276	Editorial Comment. <i>Urology</i> , 2013, 82, 1346.	0.5	0
277	Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3490-3493.	0.8	124
278	Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer. <i>BJU International</i> , 2013, 111, E167-72.	1.3	18
279	Use of Nonabsorbable Staples for Urinary Diversion: A Step in the Wrong Direction. <i>Urologia Internationalis</i> , 2013, 90, 125-129.	0.6	10
280	Short-term Change in Renal Function in Patients Undergoing Continent vs Noncontinent Urinary Diversions. <i>UroToday International Journal</i> , 2013, 06, .	0.1	2
281	Null Association Between Histology of First and Second Primary Malignancies in Men With Bilateral Testicular Germ Cell Tumors. <i>American Journal of Epidemiology</i> , 2013, 178, 1240-1245.	1.6	14
282	Radical cystectomy and orthotopic urinary diversion in male patients with pT4a urothelial bladder carcinoma: Oncological outcomes. <i>International Journal of Urology</i> , 2013, 20, 1229-1233.	0.5	10
283	Radical cystectomy with orthotopic neobladder reconstruction following prior radical prostatectomy. <i>World Journal of Urology</i> , 2012, 30, 741-745.	1.2	13
284	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. <i>World Journal of Urology</i> , 2012, 30, 807-814.	1.2	16
285	Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery. <i>European Urology</i> , 2012, 62, 677-684.	0.9	93
286	Critical Evaluation of the American Joint Committee on Cancer TNM Nodal Staging System in Patients with Lymph Node-Positive Disease after Radical Cystectomy. <i>European Urology</i> , 2012, 62, 671-676.	0.9	30
287	A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2012, 62, 523-533.	0.9	214
288	Robotic Intracorporeal Orthotopic Ileal Neobladder: Replicating Open Surgical Principles. <i>European Urology</i> , 2012, 62, 891-901.	0.9	170

#	ARTICLE	IF	CITATIONS
289	Contemporary Management of Postchemotherapy Testis Cancer. <i>European Urology</i> , 2012, 62, 867-876.	0.9	96
290	Preoperative Staging of Invasive Bladder Cancer With Dynamic Gadolinium-enhanced Magnetic Resonance Imaging: Results From a Prospective Study. <i>Urology</i> , 2012, 80, 1313-1318.	0.5	75
291	Reproductive Organ Involvement in Female Patients Undergoing Radical Cystectomy for Urothelial Bladder Cancer. <i>Journal of Urology</i> , 2012, 188, 2134-2138.	0.2	34
292	1911 FACTORS INFLUENCING LYMPH NODE YIELD DURING RADICAL CYSTECTOMY WITH EXTENDED PELVIC LYMPHADENECTOMY: SINGLE-INSTITUTION EXPERIENCE WITH A STANDARDIZED DISSECTION TEMPLATE. <i>Journal of Urology</i> , 2012, 187, .	0.2	3
293	Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus and Metastatic Caval Wall Invasion. <i>Urology</i> , 2012, 79, e6-e8.	0.5	4
294	Colocalycostomy for Repair of Ureterojejunal Fistula. <i>Urology</i> , 2012, 79, e12-e14.	0.5	1
295	Editorial Comment. <i>Urology</i> , 2012, 79, 481.	0.5	0
296	Long-term Outcomes of Open Radical Retropubic Prostatectomy for Clinically Localized Prostate Cancer in the Prostate-specific Antigen Era. <i>Urology</i> , 2012, 79, 626-631.	0.5	40
297	Editorial Comment. <i>Urology</i> , 2012, 80, 639.	0.5	0
298	Midline Extraperitoneal Approach for Retroperitoneal Lymph Node Dissection for Testicular Germ Cell Tumor. <i>Urology</i> , 2012, 80, 941-945.	0.5	16
299	Management of the Continent Cutaneous Stomal Complications. <i>Current Bladder Dysfunction Reports</i> , 2012, 7, 294-301.	0.2	3
300	Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. <i>European Urology</i> , 2012, 61, 237-242.	0.9	69
301	Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. <i>BJU International</i> , 2012, 109, 846-854.	1.3	101
302	THE VALUE OF EXTENDED TRANSURETHRAL RESECTION OF BLADDER TUMOUR (TURBT) IN THE TREATMENT OF BLADDER CANCER. <i>BJU International</i> , 2012, 110, E80.	1.3	2
303	Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. <i>BJU International</i> , 2012, 110, 1324-1324.	1.3	1
304	Adjuvant Surgery in Testicular Cancer Patients Undergoing Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2012, 19, 2388-2393.	0.7	48
305	Cryptorchidism and testicular germ cell tumors: comprehensive meta-analysis reveals that association between these conditions diminished over time and is modified by clinical characteristics. <i>Frontiers in Endocrinology</i> , 2012, 3, 182.	1.5	36
306	Mesenteric lymphadenopathy in patients with germ cell tumor.. <i>Journal of Clinical Oncology</i> , 2012, 30, 347-347.	0.8	1

#	ARTICLE	IF	CITATIONS
307	Neoadjuvant chemotherapy for muscle-invasive bladder cancer at the University of Southern California.. Journal of Clinical Oncology, 2012, 30, 301-301.	0.8	0
308	The influence of variant histology on survival outcomes of radical cystectomy for bladder cancer.. Journal of Clinical Oncology, 2012, 30, 278-278.	0.8	0
309	The impact of preoperative ASA and serum albumin on early complication and survival rate of patients undergoing radical cystectomy for bladder cancer.. Journal of Clinical Oncology, 2012, 30, 313-313.	0.8	0
310	Clinical validation of the 7th AJCC-TNM nodal staging system in lymph node-positive patients undergoing radical cystectomy.. Journal of Clinical Oncology, 2012, 30, 4588-4588.	0.8	0
311	Mortality from other malignancies in bladder cancer survivors.. Journal of Clinical Oncology, 2012, 30, 4589-4589.	0.8	0
312	1137 THE IMPACT OF INTESTINAL URINARY DIVERSION ON RENAL FUNCTION. Journal of Urology, 2011, 185, .	0.2	1
313	The management of subcentimeter residual mass in NSGCT: pcRPLND vs. observation. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 842-847.	0.8	11
314	Lymph Node Dissection Technique Is More Important Than Lymph Node Count in Identifying Nodal Metastases in Radical Cystectomy Patients: A Comparative Mapping Study. European Urology, 2011, 60, 946-952.	0.9	121
315	Evaluation and Preservation of Fertility in Patients with Testicular Cancer. Journal of Adolescent and Young Adult Oncology, 2011, 1, 25-29.	0.7	6
316	Chemoresponsive Liver Hemangioma in a Patient With a Metastatic Germ Cell Tumor. Journal of Clinical Oncology, 2011, 29, e842-e844.	0.8	4
317	The Role of Photodocumentation in Surveillance Cystoscopy for Bladder Cancer. UroToday International Journal, 2011, 04, .	0.1	0
318	Management of residual mass in nonseminomatous germ cell tumors following chemotherapy. Therapeutic Advances in Urology, 2011, 3, 163-171.	0.9	19
319	Androgen-Producing Testicular Germ Cell Tumors. Journal of Clinical Oncology, 2011, 29, e634-e635.	0.8	11
320	Improving selection of appropriate urinary diversion following radical cystectomy for bladder cancer. Expert Review of Anticancer Therapy, 2011, 11, 941-948.	1.1	40
321	Factors influencing the choice of urinary diversion in patients undergoing radical cystectomy. BJU International, 2010, 106, 654-657.	1.3	31
322	Management of Disseminated Nonseminomatous Germ Cell Tumors With Risk-Based Chemotherapy Followed by Response-Guided Postchemotherapy Surgery. Journal of Clinical Oncology, 2010, 28, 537-542.	0.8	128
323	Distinctive Morphology of Renal Cell Carcinomas in Tuberous Sclerosis. International Journal of Surgical Pathology, 2010, 18, 409-418.	0.4	41
324	753 AGE IS NOT A CONTRAINDICATION FOR AN ORTHOTOPIC ILEAL NEOBLADDER FOLLOWING RADICAL CYSTECTOMY. Journal of Urology, 2010, 183, .	0.2	1

#	ARTICLE	IF	CITATIONS
325	Editorial Comment. Urology, 2010, 76, 1001.	0.5	0
326	Renal Brucelloma in a Herniated Kidney. UroToday International Journal, 2010, 03, .	0.1	0
327	Open Partial Nephrectomy for Pediatric Renovascular Hypertension. Scientific World Journal, The, 2009, 9, 287-290.	0.8	2
328	Resection of the Inferior Vena Cava Without Reconstruction for Urologic Malignancies. Urology, 2009, 74, 1257-1262.	0.5	44
329	Re: Appendiceal substitution following right proximal ureter injury. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2009, 35, 90-91.	0.7	6
330	Re: Use of Androgen Deprivation Therapy for Metastatic Prostate Cancer in Older Men. European Urology, 2008, 54, 1201-1202.	0.9	0
331	Venous Resection in Urological Surgery. Journal of Urology, 2008, 180, 2338-2342.	0.2	28
332	Application of the Yang-Monti Channel in Adult Continent Cutaneous Urinary Diversion. Urology, 2008, 72, 828-831.	0.5	15
333	Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Human Pathology, 2007, 38, 1547-1552.	1.1	191
334	Re: Prediagnosis Prostate Specific Antigen Velocity is Associated With Risk of Prostate Cancer Progression Following Brachytherapy and External Beam Radiation Therapy. Journal of Urology, 2007, 177, 2396-2396.	0.2	1
335	A Critical Analysis of Perioperative Mortality From Radical Cystectomy. Journal of Urology, 2006, 175, 886-890.	0.2	139
336	Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer. Urology, 2006, 67, 1247-1252.	0.5	30
337	Intraoperative Renal Cell Carcinoma Tumor Embolization to the Right Atrium: Incidental Diagnosis by Transesophageal Echocardiography. Anesthesia and Analgesia, 2006, 102, 378-379.	1.1	18
338	Evolving treatment paradigms for locally advanced and metastatic prostate cancer. Expert Review of Anticancer Therapy, 2006, 6, 1639-1651.	1.1	3
339	Management of difficult germ-cell tumors. Oncology, 2006, 20, 1565-70, 1575; discussion 1575-6.	0.4	3
340	Adrenal myelolipoma: diagnosis and management. Urology Journal, 2006, 3, 71-4.	0.3	63
341	EphB4 Expression and Biological Significance in Prostate Cancer. Cancer Research, 2005, 65, 4623-4632.	0.4	129
342	PROGNOSTIC SIGNIFICANCE OF LYMPHOVASCULAR INVASION OF BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY. Journal of Urology, 2005, 174, 103-106.	0.2	121

#	ARTICLE	IF	CITATIONS
343	Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue. <i>Urology</i> , 2005, 65, 1008-1012.	0.5	11
344	Current clinical trials in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 289-292.	0.8	8
345	RADICAL CYSTECTOMY FOR PRIMARY NEUROENDOCRINE TUMORS OF THE BLADDER: THE UNIVERSITY OF SOUTHERN CALIFORNIA EXPERIENCE. <i>Journal of Urology</i> , 2005, 174, 93-96.	0.2	142
346	Primary Renal Carcinoid Tumor. <i>Scientific World Journal, The</i> , 2004, 4, 378-380.	0.8	9
347	Adenomatous Polyp of the Verumontanum Causing Bladder Outlet Obstruction. <i>Scientific World Journal, The</i> , 2004, 4, 89-91.	0.8	2
348	The importance of an extended lymphadenectomy in the management of high-grade invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 1007-1016.	1.1	17
349	PROGNOSIS OF SEMINAL VESICLE INVOLVEMENT BY TRANSITIONAL CELL CARCINOMA OF THE BLADDER. <i>Journal of Urology</i> , 2004, 172, 81-84.	0.2	25
350	PROGNOSIS OF PATIENTS WITH LYMPH NODE POSITIVE PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY: LONG-TERM RESULTS. <i>Journal of Urology</i> , 2004, 172, 2252-2255.	0.2	289
351	Microscopic and Gross Extravesical Extension in Pathological Staging of Bladder Cancer. <i>Journal of Urology</i> , 2004, 171, 640-645.	0.2	61
352	Continent right colon reservoir using a cutaneous appendicostomy. <i>Urology</i> , 2004, 63, 577-580.	0.5	24
353	Renal angiomyolipoma with liposarcomatous transformation: A case report and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 425-427.	0.8	10
354	New molecular markers for bladder cancer detection. <i>Current Opinion in Urology</i> , 2004, 14, 259-264.	0.9	38
355	Endoscopic management of upper urinary tract transitional cell carcinoma. <i>Cancer</i> , 2003, 98, 55-60.	2.0	134
356	Natural history of surgically treated bladder carcinoma with extravesical tumor extension. <i>Cancer</i> , 2003, 98, 955-961.	2.0	49
357	Puboprostatic Sling Repair for Treatment of Urethral Incompetence in Adult Neurogenic incontinence. <i>Journal of Urology</i> , 2003, 169, 199-202.	0.2	33
358	Colourachal Fistula in an Adult Presenting with Feculent Umbilical Drainage. <i>Journal of Urology</i> , 2003, 170, 184-184.	0.2	14
359	Sarcomatoid renal cell carcinoma with massive osteosarcomatous differentiation: an unusual image in clinical urology. <i>Urology</i> , 2003, 61, 1031-1032.	0.5	8
360	Benign retroperitoneal schwannoma: a case series and review of the literature. <i>Urology</i> , 2003, 62, 993-997.	0.5	124

#	ARTICLE	IF	CITATIONS
361	Metastatic adenocarcinoma of the prostate with a testicular mass and cutaneous nodules. BJU International, 2003, 92, e61.	1.3	0
362	Puboprostatic sling repair for treatment of urethral incompetence in adult neurogenic incontinence. Journal of Urology, 2003, 169, 199-202.	0.2	14
363	ENDOSCOPIC MANAGEMENT OF RENAL HEMANGIOMA. Journal of Urology, 2002, 167, 488-489.	0.2	37
364	Review of techniques to remove a Foley catheter when the balloon does not deflate. Urology, 2002, 59, 127-129.	0.5	27
365	ENDOSCOPIC MANAGEMENT OF RENAL HEMANGIOMA. Journal of Urology, 2002, 167, 488-489.	0.2	8
366	The Prognostic Significance of S&ndash;Phase Analysis in Stage Ta&sol;T1 Bladder Cancer. European Urology, 2000, 37, 595-600.	0.9	10